B. Riley downgraded Anterix (ATEX) to Neutral from Buy with a price target of $69, up from $44. Limited upside is seen amid ongoing uncertainty around monetizing 900 MHz spectrum holdings, despite four years of efforts yielding only 12 agreements covering roughly 17% of POPs, though there is potential for a near-term deal, and recent SpaceX (SPCX) and Amazon (AMZN) transactions reinforce growing recognition of spectrum as a scarce, valuable, and strategically important asset, the analyst tells investors in a research note.
